- AutoSynVax™ (ASV™), AGEN2003 clinical trials data
- Novel targets in colorectal carcinoma (CRC) for off-the-shelf vaccine with pan indication development potential
- AGEN2373, a novel, potential best-in-class anti-CD137 antibody for the treatment of human malignancies, is well-tolerated in pre-clinical studies
PR Newswire
LEXINGTON, Mass., Nov. 6, 2018